AVM Biotechnology
Seattle
About AVM Biotechnology
AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $24.3M
- Last round: Grant (Jun 2022)
- Website: avmbiotech.com
- Phone: +1 206 906 9922
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/avm-biotechnology-9809 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.